



Recombinant HIV type 1 gp41 [BGAL] (DAG553)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Recombinant Human Immunodeficiency Virus Type 1 envelope antigen, gp41, contains a Beta-galactosidase (114 kDa) fusion partner, was expressed in Ecoli, and purified in vitro using conventional chromatography techniques.
Species	HIV
Purity	~95% by SDS-PAGE (Proprietary method)
Conjugate	Beta-galactosidase
Applications	Suitable for use in ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Molecular Weight	146 kDa
Format	Liquid
Buffer	10mM Na ₂ CO ₃ , 10mM EDTA, 14mM beta-ME, 0.05% tween 20
Preservative	None
Storage	2-8°C short term, -20°C long term

BACKGROUND

Introduction	The HIV-1 envelope (Env) glycoproteins play an essential role in the virus replication cycle by mediating the fusion between viral and cellular membranes during the entry process. The Env glycoproteins are synthesized as a polyprotein precursor, gp160, that is cleaved by cellular
---------------------	--

proteases to the mature surface glycoprotein gp120 and the transmembrane glycoprotein gp41. During virus assembly the gp120/gp41 complex is incorporated as heterotrimeric spikes into the lipid bilayer of nascent virions.

Keywords

Human Immunodeficiency Virus; HIV gp41; HIV; HIV-1 gp41; HIV-1; HIV type 1 gp41
